- Condition: Hepatitis C, Chronic
Interventions: Drug: RO5024048; Drug: RO5024048; Drug: peginterferon alfa-2a [Pegasys]; Drug: ribavirin [Copegus]; Drug: danoprevir; Drug: ritonavir
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Not yet recruiting - verified May 2012 - Condition: HIV
Intervention: Drug: Rilpivirine
Sponsors: Imperial College London; Imperial College London; Janssen-Cilag Ltd.
Recruiting - verified March 2012 - Condition: HIV Related Neurocognitive Impairment
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified January 2012 - Condition: HIV
Interventions: Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: EN41-FPA2 HIV vaccine; Biological: Na Cl Placebo vaccine
Sponsors: PX'Therapeutics; PX'Therapeutics; European Commission
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: Telaprevir; Drug: Telaprevir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified April 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: NNRTI plus FTC/TDF
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir df; Drug: ritonavir-boosted protease inhibitor plus Truvada
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: Hepatitis C, Genotype 1
Interventions: Drug: BMS-790052 (Daclatasvir); Drug: Ribavirin; Drug: Peg-Interferon alfa 2a
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Condition: HIV
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified January 2012 - Condition: Hepatitis C, Chronic
Interventions: Drug: BI201335; Drug: BI201335 24W; Drug: PegIFN/RBV; Drug: PegIFN/RBV
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Condition: Lung Cancer
Interventions: Drug: nelfinavir; Radiation: Radical Radiotherapy
Sponsors: Oxford University Hospitals NHS Trust; Oxford University Hospitals NHS Trust
Not yet recruiting - verified December 2011 - Condition: HIV Infection
Intervention:
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; PENTA Foundation
Recruiting - verified March 2012 - Conditions: HIV; Impaired Cognition
Interventions: Drug: standard care; Drug: novel treatment
Sponsors: Imperial College London; Imperial College London; Pfizer
Not yet recruiting - verified June 2011 - Conditions: Human Immunodeficiency Virus (HIV) Infections; Acquired Immunodeficiency Syndrome (AIDS) Virus
Interventions: Drug: Darunavir; Drug: Ritonavir
Sponsors: Janssen-Cilag International NV; Janssen-Cilag International NV
Recruiting - verified May 2012 - Conditions: Acquired Immunodeficiency Syndrome; HIV Infections
Interventions: Drug: elvitegravir/cobicistat/emtricitabine/tenofovir DF; Drug: cobicistat and atazanavir or cobicistat and darunavir
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV, Combination Therapy
Interventions: Drug: Atazanavir; Drug: Ritonavir (heat-stable); Drug: Raltegravir; Drug: Tenofovir/Emtricitabine
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012 - Condition: HIV
Interventions: Drug: Atazanavir Sulphate; Drug: Ritonavir
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified April 2012 - Conditions: HIV; Lymphoma
Intervention:
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified October 2011 - Condition: HIV
Intervention: Drug: Raltegravir
Sponsors: Imperial College London; Imperial College London
Recruiting - verified November 2011 - Conditions: HIV Coinfection; Hepatitis C; Hepatitis B; Hepatotoxicity
Interventions: Drug: Maraviroc; Drug: Placebo
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV
Intervention: Drug: Maraviroc
Sponsors: Imperial College London; Imperial College London
Not yet recruiting - verified December 2011 - Conditions: Ewing's Sarcoma/Soft Tissue Sarcoma; Neuroblastoma; Brain Tumors
Interventions: Drug: plerixafor; Drug: plerixafor; Drug: plerixafor
Sponsors: Genzyme; Genzyme
Recruiting - verified January 2012 - Condition: HIV Infection
Interventions: Drug: Efavirenz; Drug: Efavirenz
Sponsors: Kirby Institute; Kirby Institute; Chelsea and Westminster NHS Foundation Trust
Recruiting - verified February 2012 - Condition: Chronic Hepatitis B
Interventions: Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate, Peginterferon α-2a; Drug: Tenofovir Disoproxil Fumarate; Drug: Peginterferon α-2a
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012 - Condition: HIV-1 Infection
Intervention: Drug: Rilpivirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: lersivirine; Drug: lersivirine; Drug: efavirenz; Drug: lersivirine; Drug: lersivirine; Drug: etravirine
Sponsors: Pfizer; Pfizer; ViiV Healthcare
Recruiting - verified May 2012 - Condition: HIV Infection
Intervention: Drug: Hydroxychloroquine
Sponsors: St Stephens Aids Trust; St Stephens Aids Trust
Recruiting - verified December 2011 - Condition: Antiretroviral Therapy in HIV-1 Infected Children
Interventions: Drug: Kaletra dosed once daily; Drug: kaletra dosed twice daily
Sponsors: PENTA Foundation; PENTA Foundation; Medical Research Council; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Recruiting - verified February 2012 - Conditions: HIV; AIDS; Indicator Diseases/Indicator Conditions
Interventions: Other: HIV test (serological or salivary); Other: Interview
Sponsors: Chelsea and Westminster NHS Foundation Trust; Chelsea and Westminster NHS Foundation Trust; HIV in Europe (Co-Sponsor)
Recruiting - verified October 2009 - Condition: Smoking Cessation
Intervention: Other: Respiragene test
Sponsors: University of Surrey; University of Surrey; Lab 21, Cambridge; NHS Research and Development
Recruiting - verified March 2012 - Condition: HIV-1 Infections
Interventions: Biological: ChAdV63.HIVconsv low dose.; Biological: ChAdV63.HIVconsv high dose.; Biological: pSG2.HIVconsv; Biological: MVA.HIVconsv; Other: Placebo
Sponsors: University of Oxford; University of Oxford
Recruiting - verified February 2012 - Condition: HIV-1 Infections
Interventions: Drug: Darunavir; Drug: ritonavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: ritonavir; Drug: Darunavir; Drug: Darunavir; Drug: ritonavir
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified May 2012 - Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Condition: Influenza
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: HIV Infections; HIV-1
Intervention: Drug: Etravirine
Sponsors: Janssen R&D Ireland; Janssen R&D Ireland
Recruiting - verified April 2012 - Condition: HIV Infection
Intervention: Drug: All licensed antiretroviral medications
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); Copenhagen HIV Programme (CHIP) -- Copenhagen, Denmark; Medical Research Council (MRC) Clinical Trials Unit -- London, United Kingdom; Kirby Institute; The Institute for Clinical Research at the Veterans Affairs Medical Center -- Washington, D.C., USA; French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS); German Federal Ministry of Education and Research; NEAT - European AIDS Treatment Network; National Health and Medical Research Council, Australia; National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); National Institute of Mental Health (NIMH); National Institute of Neurological Disorders and Stroke (NINDS); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); Abbott; Bristol-Myers Squibb; Gilead Sciences; GlaxoSmithKline; Merck; Tibotec Pharmaceutical Limited
Recruiting - verified April 2012 - Condition: HIV Infections
Intervention:
Sponsors: Radboud University; Radboud University; PENTA Foundation; Merck; Bristol-Myers Squibb; CIHR Canadian HIV Trials Network
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: UK-453,061 Dose 1; Drug: UK-453,061 Dose 2; Drug: Etravirine
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: HIV-1
Interventions: Drug: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed; Other: Standard of care tests if needed
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012 - Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: IGIV3I Grifols
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified January 2012 - Condition: Human Immunodeficiency Virus
Interventions: Drug: Maraviroc along with an optimized background antiretroviral drug regimen; Drug: Optimized background antiretroviral drug regimen without maraviroc
Sponsors: ViiV Healthcare; ViiV Healthcare; Pfizer
Recruiting - verified May 2012 - Condition: HIV Infections
Intervention: Drug: Tipranavir
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Available - verified May 2012
 |
Join Clinical Trials in Huntsville,Alabama |
